SG
SCNI

StoneX Group’s Scinai Immunotherapeutics SCNI Stock Holding History

StoneX Group’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56K Buy
+1,309
New +$6.44K ﹤0.01% 1420

Other funds holding SCNI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

StoneX Group's SCNI Position: Q2 2026 in Review

StoneX Group opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 1,309 shares worth $4.56K. The stake represents ﹤0.01% of the portfolio and ranks #1420 among its holdings.

11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • StoneX Group held 1,309 shares of Scinai Immunotherapeutics worth $4.56K as of Q2 2026.
  • Scinai Immunotherapeutics was a new StoneX Group position in Q2 2026.
  • Scinai Immunotherapeutics made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1420 holding.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.